Artiva Biotherapeutics, Inc. Common Stock

Day range

$5.95 – $6.25

Open

$6.15

Prev close

$6.15

Volume

269.42K

Market cap

$300.67M

Shares out

48.89M

P/E

—

P/S

—

P/B

0.87

P/FCF

—

ROE

-26.1%

ROA

-24.6%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Annual meeting resultsSep 11, 2026

  At the Annual Meeting, the Company's stockholders voted on the proposals listed below... The Company's stockholders elected the persons listed below as Class II directors each to serve a three-year term through the Company's 2029 annual meeting of stockholders.

• Shareholder meeting noticeJul 22, 2026

  Artiva Biotherapeutics, Inc. (the "Company") today announced that the expected date for the Company's 2026 annual meeting of stockholders (the "Annual Meeting") is September 8, 2026... In light of the foregoing, and in accordance with the Company's amended and restated bylaws (the "Bylaws"), in order for any business to be brought before the Annual Meeting by a stockholder and for any person to be nominated for election to the Company's board of directors at the Annual Meeting by a stockholder, such stockholder must notify the Company of such intention by notice received at the Company's principal executive offices not later than the close of business on August 1, 2026.

• Executive officer departureMay 19, 2026

  On May 18, 2026 (the "Effective Date"), Fred Aslan, M.D. resigned as President of the Company in connection with Dr. Miralles's appointment as President and Head of Research and Development of the Company as described below. Dr. Aslan remains the Company's Chief Executive Officer and a member of the Board.

• Underwriting agreementMay 8, 2026

  On May 8, 2026, Artiva Biotherapeutics, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Jefferies LLC, TD Securities (USA) LLC and Cantor Fitzgerald & Co., as representatives of the several underwriters listed therein (collectively, the "Underwriters"), to issue and sell 23,871,526 shares of the Company's common stock at a price of $11.52 per share and pre-funded warrants to purchase 2,170,138 shares of Common Stock.

• Clinical trial resultsMay 8, 2026

  On May 8, 2026, the Company issued a press release announcing positive initial clinical data from ongoing clinical trials evaluating AlloNK® (also known as AB-101) in combination with rituximab. As of the April 3, 2026 data cutoff, the initial clinical dataset includes 21 refractory rheumatoid arthritis ("RA") patients with at least 12 weeks of follow-up, including 13 patients with six months of follow-up... More than 50% of patients with six months of follow-up achieved an ACR50 response.

Days to cover

3.7

Short interest

2.3M

Avg volume

625.94K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development
  positiveGlobeNewswire Inc.· May 19, 2026
• Rheumatoid Arthritis Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape
  positiveGlobeNewswire Inc.· Apr 28, 2026
• Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference
  positiveGlobeNewswire Inc.· Apr 8, 2026
• Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant
  positiveGlobeNewswire Inc.· Feb 24, 2026
• Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
  positiveGlobeNewswire Inc.· Nov 12, 2025